Feedback / Questions
TQS-168 - Tranquis Therapeutics
https://www.businesswire.com/news/home/20220621005329/en/Tranquis-Therapeutics-Granted-FDA-Orphan-Drug-Designation-for-TQS-168-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis
Jun 21, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next